VivaGel Inhibits Clinically Relevant Strains Of Human Papillomavirus (HPV) In Laboratory Tests

Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) announced that recent studies have shown that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits clinically-relevant strains of the human papillomavirus (HPV) in laboratory tests. Starpharma CEO, Dr Jackie Fairley said: “These are exciting results which have positive implications for VivaGel(R), and which merit further investigation.

More: continued here

Filed under: Cervical Cancer on May 15th, 2008